Michael R. Megna - Jun 30, 2020 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Chief Accounting Officer
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact for Michael Megna
Stock symbol
KNSA
Transactions as of
Jun 30, 2020
Transactions value $
$22,499
Form type
4
Date filed
3/18/2022, 04:40 PM
Next filing
Sep 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Award $6.1K +641 +56.38% $9.51 1.78K Jun 30, 2020 Direct F1
transaction KNSA Class A Common Share Award $6.08K +405 +22.78% $15.02 2.18K Dec 31, 2020 Direct F2
transaction KNSA Class A Common Share Award $6.76K +588 +26.94% $11.49 2.77K Jul 15, 2021 Direct F3
transaction KNSA Class A Common Share Award $6.29K +653 +23.57% $9.63 3.42K Jan 15, 2022 Direct F4
transaction KNSA Class A Common Share Options Exercise +775 +22.63% 4.2K Mar 16, 2022 Direct F5
transaction KNSA Class A Common Share Tax liability -$2.72K -269 -6.41% $10.13 3.93K Mar 16, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -775 -25.02% $0.00 2.32K Mar 16, 2022 Class A Common Share 775 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 1, 2020 to June 30, 2020. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
F2 The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 1, 2020 to December 31, 2020. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
F3 The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 1, 2021 to July 15, 2021. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
F4 The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2021 to January 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
F5 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F6 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.